Completed PHASE2 INTERVENTIONAL 3-arm NCT00103727

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

Sponsor: GlaxoSmithKline

Conditions Schizophrenia

Interventions Talnetant placebo risperidone

Updated 7 times since 2017 Last updated: Apr 27, 2015 Started: Dec 31, 2004 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00103727, this PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Austin, United States , Cerritos, United States , Clementon, United States , Garden Grove, United States , Glendale, United States , Irving, United States , Little Rock, United States , National City, United States and 11 more locations